| Price | $0.16 |
| Year Range | $0.13 – $1.71 |
| Market Cap | $5.1M |
| Industry | Medical Devices |
What Is Vivos Therapeutics’s AI Stock Analysis?
Vivos Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Vivos Therapeutics’s momentum in near-real time.
Vivos Therapeutics (VVOS) has an AltIndex AI Score of 48/100, currently a Hold signal. The AI Score distills Vivos Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Vivos Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Vivos Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving VVOS’s AI Score?
Fundamentals
Revenue for the last quarter was $5.2M. This is an increase of 0.23% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 34.90%, suggesting positive year-over-year growth. Net income for the last quarter was $-5.5M. This is an increase of -29.29% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 9.34%, which may be a cause for concern. Ebitda for the last quarter was $-5M. This is an increase of -31.30% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 6.50%, which may be a cause for concern.
See Vivos Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $0.16. This represents a decrease of 5.88% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 94.87%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $0.15, which is higher than the previous SMA10 of $0.15. This indicates a potential upward trend in price movement. The RSI is 44.1, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Vivos Therapeutics has an estimate of 2,000 visitors to their webpage. The number of visitors is down by -75% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Vivos Therapeutics’s job postings, web traffic and app downloads.
Frequently Asked Questions: Vivos Therapeutics AI Stock Analysis
Vivos Therapeutics's AltIndex AI Score is 48/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Vivos Therapeutics a Hold (48/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Vivos Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the VVOS AI Score or sign up to read the full thesis.
